• Edwards Lifesciences ($EW) announced finalizing its $340M cash-and-stock acquisition of Valtech Cardio. The deal was announced in November 2016. Valtech is based out of Israel and develops Cardioband System for transcatheter repair of the mitral and tricuspid valves.
Under the terms of the merger agreement, Edwards paid $340 million in stock and cash for Valtech at closing, subject to some adjustments. In addition, there is also the potential for up to $350 million in pre-specified milestone-driven payments over the next 10 years.
• Leap Therapeutics (LPTX) announced the completion of merger with Macrocure ($MCUR). Leap Therapeutics, Inc. is a biotechnology company developing targeted and immuno-oncology therapeutics. Post-merger, Macrocure became a wholly-owned subsidiary of Leap.
Leap will be listed on The Nasdaq Global Market under the symbol “LPTX”. The stock is expected to begin trading on Tuesday, January 24, 2017. Leah has two major drug candidates in the pipeline